A retrospective study to evaluate the impact of proteinuria induced by Atezolizumab plus Bevacizumab on renal function and other renal-related adverse events in patients with unresectable hepatocellular carcinoma.
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000050692
- Lead Sponsor
- Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients with missing UPCR and eGFR data at baseline (2)Patients with all missing UPCR and eGFR data after starting Atezo+Bev treatment (3)Patients with Child-Pugh Classification Class C at the start of Atezo+Bev treatment (4)Patients deemed ineligible for this study by their physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method